196
Participants
Start Date
September 10, 2018
Primary Completion Date
December 30, 2022
Study Completion Date
December 30, 2022
PDR001
400 mg of PDR001 administered every 4 weeks intravenously
LAG525
600 mg of LAG525 administered every 4 weeks intravenously
INC280
400 mg of INC280 administered twice daily orally
ACZ885
200 mg of ACZ885 administered every 4 weeks subcutaneosuly
LEE011
600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
Novartis Investigative Site, North Sydney
Novartis Investigative Site, Westmead
Novartis Investigative Site, Zurich
NYU Laura and Isaac Perlmutter Cancer Center Perlmutter Cancer Center, New York
Novartis Investigative Site, Marseille
University of Pittsburgh Medical Center, Pittsburgh
Novartis Investigative Site, Milan
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Kiel
Novartis Investigative Site, Bergamo
Novartis Investigative Site, Madrid
Novartis Investigative Site, Essen
Novartis Investigative Site, Paris
Novartis Investigative Site, Napoli
Novartis Investigative Site, München
The Angeles Clinic and Research Institute, Los Angeles
University of California Los Angeles, Los Angeles
UCSF Medical Center ., San Francisco
Novartis Investigative Site, Villejuif
Massachusetts General Hospital Massachusetts Gen. Hospital CC, Boston
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Dresden
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Barcelona
Novartis Investigative Site, L'Hospitalet de Llobregat
Novartis Investigative Site, Northwood
Novartis Investigative Site, London
Novartis Investigative Site, Manchester
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY